Apellis Pharmaceuticals, Inc. - Common Stock (APLS)

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / Common Stock
Shares outstanding
127,672,444
Total 13F shares
64,568,091
Share change
-210,142
Total reported value
$4,081,020,359
Put/Call ratio
86%
Price per share
$63.20
Number of holders
200
Value change
+$9,798,661
Number of buys
117
Number of sells
76

Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2021

As of 30 Jun 2021, Apellis Pharmaceuticals, Inc. - Common Stock (APLS) was held by 200 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 64,568,091 shares. The largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, HHLR ADVISORS, LTD., JENNISON ASSOCIATES LLC, BAKER BROS. ADVISORS LP, STATE STREET CORP, VICTORY CAPITAL MANAGEMENT INC, and Farallon Capital Management LLC. This page lists 201 institutional shareholders reporting positions in this security for the Q2 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.